For generations, people have suffered from brain cancers, neurodegenerative diseases, and metabolic disorders, and most drugs haven’t been optimized to deliver the right amount of dosage to the brain. One reason for that is the blood-brain barrier. That’s why in this episode, we take a look at Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF). Their proprietary brain delivery technology, the xB3³ platform, transports medicine across the blood-brain barrier to offer a more successful treatment for diseases of the central nervous system. We take a look at their tech, their stock price and financials. Tune in!
Bioasis Technologies (BTI.V): To Invest or Not?
Latest Articles
- Soma Gold (SOMA.V): Fully funded, profitable, and undervalued
- BioNxt (BNXT.C) rips as European Patent Office backs Cladribine thin-film
- Video: Alta Copper CEO is buying ATCU as the stock rocks
- Prismo Metals (PRIZ.C) raises half a mill; now It’s time to put it to work
- NetraMark Holdings (AIAI.C): Failed FDA trials cost billions, NetraAI may prevent them
Top Searches
Abitibi Greenstone Belt Barrick Gold best canadian cannabis company biotech Bitcoin blockchain bullion Canada cannabis CBD China Chris Parry covid cryptocurrency DEFN.V Fraser Institute gambling Gold gold price. gold prices Greg Nolan hemp inflation interest rates investing investments lithium Lukas Kane marijuana mining money Newmont Goldcorp Nexus Gold pharmaceuticals psychedelics resources shrooms stock market stocks technology trading uranium wealth wealth creation weed
by
Leave a Reply